Cited by 1,821Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchDementia and Cognitive Impairment Research

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models

Open access
Ittner, Lars M., Ke, Yazi D., Delerue, Fabien, Bi, Mian, Gladbach, Amadeus, van Eersel, Janet, Wölfing, Heidrun, Chieng, Billy C. +6 more·2010·Cell

Abstract

Alzheimer's disease (AD) is characterized by amyloid-beta (Abeta) and tau deposition in brain. It has emerged that Abeta toxicity is tau dependent, although mechanistically this link remains unclear. Here, we show that tau, known as axonal protein, has a dendritic function in postsynaptic targeting of the Src kinase Fyn, a substrate of which is the NMDA receptor (NR). Missorting of tau in transgenic mice expressing truncated tau (Deltatau) and absence of tau in tau(-/-) mice both disrupt postsynaptic targeting of Fyn. This uncouples NR-mediated excitotoxicity and hence mitigates Abeta toxicity. Deltatau expression and tau deficiency prevent memory deficits and improve survival in Abeta-forming APP23 mice, a model of AD. These deficits are also fully rescued with a peptide that uncouples the Fyn-mediated interaction of NR and PSD-95 in vivo. Our findings suggest that this dendritic role of tau confers Abeta toxicity at the postsynapse with direct implications for pathogenesis and treatment of AD.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2010.06.036

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In AD models, absence of tau rescues behavioral impairments and reduces neurotoxicity despite no significant changes in Aβ levels.

    “For example, in AD models, the absence of tau has been shown to rescue behavioral impairments and reduce neurotoxicity, despite no significant changes in Aβ levels [75–79].”
  • In multiple mouse disease models, tau ablation is associated with protective effects.

    “Interestingly, in multiple mouse disease models, tau ablation has been associated with protective effects.”
  • The literature has established a role for tau in regulating glutamatergic synaptic function, where it interacts with Fyn, NMDARs, PSD-95, and SynGAP1.

    “The literature has established a role for tau in regulating glutamatergic synaptic function, where it interacts with Fyn, NMDARs, PSD-95, and SynGAP1 [41, 77, 105].”
  • Once tau is eliminated, glia appear better able to mount context and disease-appropriate responses, including elimination of toxic species, reduction in kinase activation, and modulation of downstream signaling, potentially explaining the broad protective effects of tau ablation across pathological models.

    “Once tau is eliminated, glia appear better able to mount context and disease-appropriate responses, including elimination of toxic species [144], reduction in kinase activation, and modulation of downstream signaling [76, 78, 145], potentially explaining the broad protective effects of tau ablation across pathological models.”
  • Growing evidence indicates a critical interplay between Aβ and tau pathologies that drives disease progression, potentially through synapses and glial activation.

    “A growing body of evidence highlights the critical interplay between these pathologies, potentially through synapses and glial activation, that drives disease progression.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., Eckert, A., Staufenbiel, M., Hardeman, E., & Götz, J.
Affiliations
  • The University of Sydney (AU)
  • University of Basel (CH)
  • Novartis (Switzerland) (CH)
  • UNSW Sydney (AU)
Corresponding author
  • Ittner, Lars M.
  • Götz, Jürgen
Venue
Cell
Publisher
Elsevier BV
Published
2010-08
Volume
142
Issue
3
Pages
387-397
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2022532556
Cited by
1,821
References
65
Citations by year
2026: 65 · 2025: 103 · 2024: 80 · 2023: 109 · 2022: 110 · 2021: 139 · 2020: 147 · 2019: 117 · 2018: 146 · 2017: 115 · 2016: 118 · 2015: 120 · 2014: 114 · 2013: 108 · 2012: 98
FWCI
73.45
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Australian Research Council
  • National Health and Medical Research Council
  • National Medical Research Council
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
tau protein, amyloid-beta toxicity, Alzheimer's disease, Fyn, NMDA receptor, excitotoxicity, PSD-95, APP23 transgenic mice, memory impairment, truncated tau
MeSH terms
Disks Large Homolog 4 Protein, Alzheimer Disease, Animals, Brain, Dendrites, Humans, Membrane Proteins, Memory Disorders, Mice, Transgenic, Synapses, Receptors, N-Methyl-D-Aspartate, Amyloid beta-Peptides, tau Proteins, Intracellular Signaling Peptides and Proteins, Proto-Oncogene Proteins c-fyn, Mice, Guanylate Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review